ZJK-807:KRASG12D的选择性PROTAC降解剂 克服胰腺癌中的抵抗
Zhaojuan Liu1, Heping Zheng1, Yanqing Tian1
1Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Journal of medicinal chemistry
|September 25, 2025
概括
一种新型的PROTAC药物ZJK-807有效降解胰腺癌细胞中的KRASG12D. 这种突破性的疗法克服了来自二次突变的抗性,为难以治疗的癌症提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- KRASG12D突变驱动胰腺癌,由于KRAS的无药性,这给治疗带来了重大挑战.
- 通过二次突变获得对KRAS抑制剂的耐药性,如MRTX1133,限制了治疗的有效性.
研究的目的:
- 开发和表征ZJK-807,一种基于大脑细胞 (CRBN) 的新型蛋白解向化马体 (PROTAC),用于选择性降解KRASG12D.
- 评估ZJK-807在克服抗药性机制方面的疗效及其在临床前模型中的治疗潜力.
主要方法:
- 设计和合成ZJK-807,一个PROTAC将KRASG12D抑制剂与CRBN配体结合在一起.
- 在体外评估KRASG12D降解,突变特异性细胞毒性和癌症细胞系中抗性克服.
- 转录组分析以阐明ZJK-807的分子作用机制.
- 在异种移植模型中对ZJK-807的抗瘤活性和药理动学的体内评估.
主要成果:
- ZJK-807可以选择性地降解KRASG12D (DC50 = 79.5 ± 5.4 nM),对野生类型KRAS或其他突变产生最小的影响.
- ZJK-807表现出强大的突变特异性细胞毒性,并克服了MRTX1133失败的二次突变所赋予的抗性.
- 转录组分析揭示了RAS/MAPK信号的抑制和TNF信号和核糖体生物发生的独特调制.
- 在体内研究表明,ZJK-807在具有良好的药理动力学的AsPC-1异种移植中实现了47%的瘤生长抑制.
结论:
- ZJK-807代表了一种基于CRBN的新型PROTAC,具有强大和选择性的KRAS降解能力.
- 这种方法有效地克服了与二次突变相关的抗性,为KRASG12D驱动的癌症提供了有希望的治疗策略.
- ZJK-807建立了一种突破性的方法,用于向恶性瘤中耐药的KRASG12D突变.
更多相关视频
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...


